To date, dozens of small molecule AURKA-specific inhibitors or pan-aurora kinase inhibitors have been developed, and 11 of these inhibitors have been evaluated in at least one complete clinical trial for patients with cancer (Table 1). Here, AURKA is linked to cancer.